Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066844 · ClinicalTrials.gov registry record · Phase 2
Navigator vs Standard Needle Injection for Hip
A Phase 2 study of Hip Pain Etiology Unknown, sponsored by Cartiva.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02066844 is a Phase 2 study of Hip Pain Etiology Unknown that has completed, run by Cartiva. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02066844, a Phase 2 study of Hip Pain Etiology Unknown, has completed, sponsored by Cartiva.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this randomized, parallel-group, single-blinded, single center, Phase II study is to collect data to compare the comfort and patient satisfaction of a hip injection delivered via the Navigator compared to a standard needle injection. In addition, delivery preparation will be compared between a Navigator injection and a standard hip injection. The data collected from this pilot study will serve as the basis to design a larger multi-center study.
Conditions Studied
Interventions
- DRUG Lidocaine
- DRUG Celestone
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02066844
The ClinicalTrials.gov registry entry for NCT02066844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cartiva, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hip Pain Etiology Unknown appearing as the primary indexed condition, and to 2 interventions - of which Lidocaine is the first listed.
NCT02066844 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02066844 about?
NCT02066844 is a clinical study titled "Navigator vs Standard Needle Injection for Hip". The purpose of this randomized, parallel-group, single-blinded, single center, Phase II study is to collect data to compare the comfort and patient satisfaction of a hip injection delivered via the Navigator compared to a standard needle injection. In addition, delivery preparation will be compared ...
What is the current status of trial NCT02066844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2014-02. Estimated completion is 2014-08.
What conditions does trial NCT02066844 study?
This clinical trial studies the following conditions: Hip Pain Etiology Unknown.
What interventions are being tested in trial NCT02066844?
The interventions under investigation include: Lidocaine (DRUG), Celestone (DRUG).
Who is sponsoring clinical trial NCT02066844?
This trial is sponsored by Cartiva, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02066844 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.